Key result
EMD 57,033 increased cardiac contractile force in rats and dogs without reducing blood pressure or increasing heart rate, consistent with calcium sensitization rather than PDE III inhibition.
Population
Anesthetized rats, anesthetized dogs, and conscious dogs
Comparison
EMD 57,033 (Ca2+ sensitizer) vs EMD 57,439, pimobendan, and milrinone
Design
Preclinical
Authors
Loading...
Supports calcium sensitization as inotropic strategy in animal models; leaves open translation to human heart failure therapy.
In vivo evidence demonstrates that EMD 57,033 increases cardiac contractile force through calcium sensitization without the adverse hemodynamic effects associated with PDE III inhibitors.
Haeusler et al. (1997) studied this question. EMD 57,033 vs. EMD 57,439, pimobendan, and milrinone was evaluated on Left ventricular first derivative of change in systolic pressure over time (dP/dt max), blood pressure, and heart rate. EMD 57,033 increased cardiac contractile force in rats and dogs without reducing blood pressure or increasing heart rate, consistent with calcium sensitization rather than PDE III inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: